This Week's Three Fallers
Three different problems put the same three tickers at the bottom of Stoxcraft's screener this week. On Holding (ONON) is down about 20% after missing sales estimates. Cellebrite (CLBT) is down about 29% after a guidance cut, an earnings miss, and a surprise CEO change all hit on the same day.
Beyond Meat (BYND) executed a reverse stock split to avoid delisting, producing a genuinely misleading headline number on some trackers. Here's what actually happened to each name, and what Stoxcraft's own scores say about them.
On Holding (ONON): Worst Day on Record on a Sales Miss
On Holding, the Swiss maker of On running shoes, fell as much as 22% on August 11 after reporting second-quarter net sales of CHF 850.3 million, below the CHF 878-881 million analysts expected. It was the stock's worst single-day decline since going public in 2021, and shares remain down about 20% for the week.
The miss sits awkwardly next to the rest of the report: adjusted EPS of CHF 0.31 beat estimates, direct-to-consumer sales grew 34% at constant currency, and gross margin hit an industry-leading 65.4%, prompting management to raise its full-year margin guidance even as it flagged slower Americas wholesale growth, just 13% at constant currency versus 17% in Q1. On Stoxcraft's scorecard, that split shows up clearly: a Health Score of 6.2 and a Piotroski Score of 7 out of 9 point to genuinely solid fundamentals behind the bad quarter, but the Performance Score has been pushed all the way down to 0 by the price reaction, and the stock now trades 37% below its 52-week high. The 1.5-star Overall Rating reflects a business that's still fundamentally sound but priced for disappointment right now.
Cellebrite (CLBT): A Guidance Cut and a Surprise CEO Change, Same Day
Cellebrite, the Israeli digital-forensics software maker, sank as much as 29% on August 13 after reporting Q2 revenue of $131.14 million, just short of the $131.87 million consensus, and guiding third-quarter and full-year 2026 sales below Wall Street's estimates. Adjusted EPS of $0.11 actually met expectations, but the guidance cut overwhelmed that beat. The same day, the company announced that Shiven Ramji, who had only joined in May as President of Products and Technology, was taking over as CEO with immediate effect.
Volume that day ran more than 1,300% above the three-month average, and a Form 144 filing showing the outgoing CEO's plan to sell roughly 339,000 shares added further pressure. On Stoxcraft's scorecard, Cellebrite's Health Score of 4.8 is middling but not alarming — the balance sheet carries very little debt and strong operating cash flow — while the Performance Score has collapsed to 2.3 after this week's move, and the Risk Score of 7.9 reflects just how sharp the single-day drop was. The 1.5-star Overall Rating captures a stock whose growth products (Guardian, Pathfinder, Corellium) are still expanding fast, but whose near-term execution and leadership stability are now in question.
Beyond Meat (BYND): The "97% Loss" That Isn't One
Beyond Meat's stock fell to a record low of $0.42 on August 11, down 19.69% on the day, after months of trading below Nasdaq's $1 minimum bid price requirement. Rather than fix the underlying business, the board executed a 1-for-30 reverse stock split, effective August 13, that combined every 30 shares into one and reset the quoted price roughly 30-fold higher when trading resumed August 14. Some data providers, comparing a pre-split price to a post-split price without adjusting for the ratio, are currently showing BYND down as much as 97% for the week — that number is a data artifact of the split, not a real investor loss.
The real story has nothing to do with the split math. Beyond Meat's revenue continues to shrink at a double-digit pace, U.S. and international foodservice sales both fell sharply, and an October 2025 debt exchange added new secured notes and diluted existing holders to buy time rather than fix demand. On Stoxcraft's scorecard, Beyond Meat's Performance Score is 0 and its Health Score is 3.6, with the stock down 84% over the past year even before this week's technical reset. The 1-star Overall Rating is the weakest of this week's three fallers — a reverse split changes the sticker price, not the underlying picture. The company must hold a $1 closing bid for ten straight business days by August 31 to keep its Nasdaq listing.
Lined up side by side, Stoxcraft's own scorecard makes the difference between these three drops obvious: one fundamentally sound business having a bad quarter, one leadership crisis layered on top of a real miss, and one survival story wearing a stock-split costume. Risk Score runs in the opposite direction from Health and Performance: the higher the number, the more volatile and fundamentally strained the stock.
On Holding carries the strongest fundamentals of the three on that scorecard, with a Health Score of 6.2 and a Piotroski Score of 7 out of 9 that both point to a genuinely sound balance sheet behind this week's price reaction. The 1.5-star Overall Rating and a Risk Score of 6.1, the mildest of this week's three fallers, capture the tension here: a business that didn't break, priced this week as if it did.
Beyond this week's snapshot, all three names stay trackable on the Stoxcraft Screener as their scores keep moving. Pull up the full comparison below to see how each stacks up right now:
Outlook: What to Watch Next
On Holding's next test is the Americas wholesale number in Q3, and whether 34% DTC growth can keep offsetting a slowing wholesale channel; the company also hosts an Investor Day on September 21-22 in Zurich, where longer-term targets could move the stock either way. Cellebrite's near-term story is now about stability as much as growth: whether new CEO Shiven Ramji can steady execution while growth products like Guardian and Corellium keep expanding, and whether the outgoing CEO's planned share sale adds further overhang. Beyond Meat has a hard deadline: it must close at $1 or above for ten consecutive business days by August 31 to keep its Nasdaq listing, and even a successful reset doesn't touch the double-digit revenue decline driving the stock lower in the first place.
None of the three has a scheduled catalyst in the next two weeks, so barring new news, expect all three to trade on broader market sentiment until the next earnings date, investor day, or compliance deadline lands.
